SEARCH

SEARCH BY CITATION

References

  • 1
    Allen JR, Carstens LA, Katagiri GJ. Hepatic veins of monkeys with venoocclusive disease: sequential ultrastructural changes. Arch Pathol 1969; 87: 279289.
  • 2
    Brooks SEH, Miller CG, McKenzie K, Audretsch JJ, Bras G. Acute veno-occlusive disease of the liver. Arch Pathol 1970; 89: 507520.
  • 3
    Rappaport AM, Knoblauch M, Zelin S, Summerell J, Bras G. Experimental hepatic veno-occlusive disease: in vivo microcircu-latory study. Adv Microcirc 1969; 2: 6979.
  • 4
    Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19: 11711180.
  • 5
    DeLeve LD. Dacarbazine toxicity in murine liver cells: a novel model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 1994; 268: 12611270.
  • 6
    Sterneck M, Wiesner R, Ascher N, Roberts J, Ferrell L, Ludwig J, Lake J. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991; 14: 806810.
  • 7
    Liano F, Moreno A, Matesanz R, Teruel JL, Redondo C, Garcia Martin F, Orte L. et al. Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause? [see comments]. Nephron 1989; 51: 509516.
  • 8
    Lemley DE, DeLacy LM, Seeff LB, Ishak KG, Nashel DJ. Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis [see comments]. Ann Rheum Dis 1989; 48: 342346.
  • 9
    Ramalho HJ, Terra EG, Cartapatti E, Barberato JB, Alves VA, Gayotto LC, Abbud Filho M.s Hepatotoxicity of azathioprine in renal transplant recipients. Transplant Proc 1989; 21: 17161717.
  • 10
    Haboubi NY, Ali HH, Whitwell HL, Ackrill P. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am J Gastroenterol 1988; 83: 256261.
  • 11
    Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 1988; 38: 258261.
  • 12
    Gerlag PG, van Hooff JP. Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment: a cause of chronic liver disease after kidney transplantation. Transplant Proc 1987; 19: 36993703.
  • 13
    Adler M, Delhaye M, Deprez C, Hardy N, Gelin M, De Pauw L, Vereerstraeten P. et al. Hepatic vascular disease after kidney transplantation: report of two cases and review of the literature. Nephrol Dial Transplant 1987; 2: 183188.
  • 14
    Jones MC, Best PV, Catto GR. Is nodular regenerative hyperpla-sia of the liver associated with azathioprine therapy after renal transplantation? Nephrol Dial Transplant 1988; 13620: 1233613872.
  • 15
    Liano F, Moreno A, Teruel JL, Lamas S, Matesanz R, Ortuno J. Hepatic veno-occlusive disease and renal transplantation [letter]. Ann Intern Med 1986; 105: 625626.
  • 16
    Read AE, Wiesner RH, LaBrecque DR, Tifft JG, Mullen KD, Sheer RL, Petrelli M. et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 1986; 104: 651655.
  • 17
    Katzka DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD. Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology 1986; 90: 446454.
  • 18
    Gerlag PG, Lobatto S, Driessen WM, Deckers PF, van Hooff JP, Schroeder E, Assmann KM. et al. Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment after kidney transplantation. J Hepatol 1985; 1: 339348.
  • 19
    Eisenhauer T, Hartmann H, Rumpf KW, Helmchen U, Scheler F, Creutzfeldt W. Favourable outcome of hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine, treated by portacaval shunt: report of a case and review of the literature. Digestion 1984; 30: 185190.
  • 20
    Mion F, Napoleon B, Berger F, Chevallier M, Bonvoisin S, Descos L. Azathioprine induced liver disease: nodular regenerative hy-perplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 1991; 32: 715717.
  • 21
    Gane E, Portmann B, Saxena R, Wong P, Ramage J, Williams R. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994; 20: 8894.
  • 22
    Mion F. Venocclusive disease after sliver-transplantation: association of an acute cellular rejection and azathioprine-induced hepatotoxicity. Gastroenterol Clin Biol 1994; 17: 867.
  • 23
    Wanless IR, Godwin TA, Allen F, Feder A. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. Medicine 1994; 59: 367379.
  • 24
    Dubuisson L, Boussarie L, Bedin C-A, Balabud C, Bioulac-Sage P. Transformation of sinusoids into capillaries in a rat model of selenium-induced nodular regenerative hyperplasia: an immu-nolight and immunoelectron microscopic study. Hepatology 1995; 21: 805814.
  • 25
    Kurowski V, Iven H. Plasma concentrations and organ distribution of thiopurines after oral application of azathioprine in mice. Cancer Chemother Pharmacol 1991; 28: 714.
  • 26
    Kaplowitz N. Enzymatic thiolysis of azathioprine in vitro. Bio-chem Pharmacol 1976; 25: 24212426.
  • 27
    Kaplowitz N, Kuhlenkamp JF. Inhibition of hepatic metabolism of azathioprine in vivo. Gastroenterology 1978; 74: 9092.
  • 28
    Kaplowitz N. Interaction of azathioprine and glutathione in the liver of the rat. J Pharmacol Exp Ther 1977; 200: 479486.
  • 29
    Willmot FC, Robertson GW. Senecio disease, or cirrhosis of the liver due to senecio poisoning. Lancet 1920; 848849.
  • 30
    Selzer G, Parker RGF. Senecio poisoning exhibiting as Chiari's syndrome. Am J Pathol 1950; 27: 885907.
  • 31
    Bras G, Jeliffe DB, Stuart KL. Veno-occlusive disease of the liver with nonportal type of cirrhosis occurring in Jamaica. Arch Pathol 1954; 57: 285300.
  • 32
    Bras G, Berry DM, György P. Plants as aetiological factor in veno-occlusive disease of the liver. Lancet 1957; 1: 960962.
  • 33
    Krishnamachari KAVR, Bhat RV, Krishnamurthi D, Krishnas-wamy K, Nagarajan V. Aetiopathogenesis of endemic ascites in Surguja district of Madhya Pradesh. Ind J Med Res 1977; 65: 672678.
  • 34
    Chauvin P, Dillon JC, Moren A. [An outbreak of Heliotrope food poisoning, Tadjikistan, November 1992-March 1993]. Sante 1994; 4: 263268.
  • 35
    Mattocks AR. Toxicity of pyrrolizidine alkaloids. Nature 1968; 217: 723728.
  • 36
    Lafranconi WM, Huxtable RJ. Hepatic metabolism and pulmonary toxicity of monocrotaline using isolated perfused liver and lung. Biochem Pharmacol 1984; 33: 24792484.
  • 37
    Mattocks AR, White INH. The conversion of pyrrolizidine alkaloids to n-oxides and to dihydropyrrolizidine derivatives by rat-liver microsomes in vitro. Chem Biol Interact 1971; 3: 383396.
  • 38
    Hilliker KS, Garcia CM, Roth RA. Effects of monocrotaline and monocrotaline pyrrole on 5-hydroxytryptamine and paraquat uptake by lung slices. Res Commun Chem Pathol Pharmacol 1983; 40: 179197.
  • 39
    Reed RL, Miranda CL, Kedzierski B, Henderson MC, Buhler DR. Microsomal formation of a pyrrolic alcohol glutathione conjugate of the pyrrolizidine alkaloid senecionine. Xenobiotica 1992; 22: 13211327.
  • 40
    Pan LC, Wilson DW, Lamé MW, Jones AD, Segall HJ. Cor pulmo-nale is caused by monocrotaline and dehydromonocrotaline, but not by glutathione or cysteine conjugates of dihydropyrrolizidine. Toxicol Appl Pharmacol 1993; 118: 8797.
  • 41
    Teicher BA, Crawford JM, Holden SA, Lin Y, Cathcart KNS, Luchette CA, Flatow J. Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide. Cancer 1988; 62: 12751281.
  • 42
    Yan CC, Huxtable RJ. Relationship between glutathione concentration and metabolism of the pyrrolizidine alkaloid, monocrotaline, in the isolated perfused liver. Toxicol Appl Pharmacol 1995; 130: 132139.
  • 43
    Mosman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Im-munol Methods 1983; 65: 5563.
  • 44
    Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936942.
  • 45
    Fariss MW, Reed DJ. High-performance liquid chromatography of thiols and disulfides: dinitrophenol derivatives. Methods En-zymol 1987; 143: 101109.
  • 46
    Martin J, White INH. Fluorimetric determination of oxidised and reduced glutathione in cells and tissues by high-performance liquid chromatography following derivatization with dansyl chloride. J Chromatogr 1991; 568: 219225.
  • 47
    Jones DP, Maellaro E, Jiang S, Slater AFG, Orrenius S. Effects of N-acetyl- L -cysteine on T-cell apoptosis are not mediated by increased cellular glutathione. Immunol Lett 1995; 45: 205209.
  • 48
    Reed DJ, Babson TR, Beetty DW, Brodie AE, Ellis WW, Potter DW. High-performance liquid chromatography analysis of nano-mole levels of glutathione, glutathione disulfide, and selected thiols and disulfides. Anal Biochem 1980; 106: 5562.
  • 49
    Baumgarten H. A simple microplate assay for the determination of cellular protein. J Immunol Methods 1985; 82: 2537.
  • 50
    Stolz A, Rahimi-Kiani M, Ameis D, Chan E, Ronk M, Shively JE. Molecular structure of rat hepatic 3a-hydroxysteroid dehy-drogenase: a member of the oxidoreductase gene family. J Biol Chem 1991; 266: 1525315257.
  • 51
    Wilson DW, Segall HJ, Pan LC, Lame MW, Estep JE, Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 1992; 22: 307325.
  • 52
    Hoorn CM, Wagner JG, Roth RA. Effects of monocrotaline pyrrole on cultured rat pulmonary endothelium. Toxicol Appl Pharmacol 1993; 120: 281287.
  • 53
    Owens CW, Belcher RV. A colorimetric micro-method for the determination of glutathione. Biochem J 1965; 94: 705711.
  • 54
    Yi J, Lu S, Fernández-Checa JC, Kaplowitz N. Expression cloning of a rat hepatic reduced glutathione transporter with canalic-ular characteristics. J Clin Invest 1994; 93: 18411845.
  • 55
    Yi J, Lu S, Fernández-Checa JC, Kaplowitz N. Expression cloning of the cDNA for a polypeptide associated with rat hepatic sinusoidal reduced glutathione transport: characteristics and comparison with the canalicular transporter. Proc Natl Acad Sci USA 1995; 92: 14951499.
  • 56
    Lash LH, Hagen TM, Jones DP. Exogenous glutathione protects intestinal epithelial cells from oxidation injury. Proc Natl Acad Sci U S A 1986; 83: 46414645.
  • 57
    Hagen TM, Jones DP. Transepithelial transport of glutathione in vascularly perfused small intestine of rat. Am J Physiol 1987; 252: G607G613.
  • 58
    Vincenzini MT, Favilli F, Inatomasa T. Glutathione-mediated transport across intestinal brush-border membranes. Biochim Biophys Acta 1988; 942: 107114.
  • 59
    Hagen TM, Brown LA, Jones DP. Protection against paraquat-induced injury by exogenous GSH in pulmonary alveolar type II cells. Biochem Pharmacol 1986; 35: 45374542.
  • 60
    Garcia-Ruiz C, Fernández-Checa JC, Kaplowitz N. Bidirectional plasma membrane transport of reduced glutathione in intact hepatocytes and membrane vesicles. J Biol Chem 1992; 267: 2225622264.
  • 61
    Kannan R, Kuhlenkamp JF, Jeandidier E, Trinh H, Ookhtens M, Kaplowitz N. Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J Clin Invest 1990; 85: 20092013.